Obesity management for the treatment of type 2 diabetes

Diabetes Care

Volumn 40, Issue , 2017, Pages S57-S63

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; AMFEBUTAMONE PLUS NALTREXONE; AMYLIN DERIVATIVE; ANTIHISTAMINIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GABAPENTIN; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOCORTICOID; HEMOGLOBIN A1C; INSULIN DERIVATIVE; LIRAGLUTIDE; LORCASERIN; METFORMIN; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; PHENTERMINE PLUS TOPIRAMATE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TETRAHYDROLIPSTATIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ARTICLE; BEHAVIOR THERAPY; BRADYCARDIA; CALORIC RESTRICTION; CLINICAL TRIAL (TOPIC); CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FLATULENCE; GASTROINTESTINAL SURGERY; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE; LIVER FAILURE; MALABSORPTION; MANIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PANCREATITIS; PARESTHESIA; PHYSICAL ACTIVITY; SEROTONIN SYNDROME; SIDE EFFECT; SUICIDAL IDEATION; VALVULAR HEART DISEASE; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

EID: 85009160019     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-S010     Document Type: Article

References (70)

1. Tuomilehto J. The emerging global epidemic of type 1 diabetes. Curr Diab Rep 2013;13:795-804
2. Knowler WC, Barrett-Connor E, Fowler SE, et al. ; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
3. UK Prospective Diabetes Study 7. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting type II diabetic patients, UKPDS Group. Metabolism 1990;39:905-912
4. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16:397-415
5. Pastors JG, Warshaw H, Daly A, Franz M, Kulkarni K. The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care 2002;25:608-613
6. Lim EL, Hollingsworth KG, Aribisala BS, Chen MJ, Mathers JC, Taylor R. Reversal of type 2 diabetes: normalisation of beta cell function in association with decreased pancreas and liver triacylglycerol. Diabetologia 2011;54:2506-2514
7. Jackness C, Karmally W, Febres G, et al. Very low-calorie diet mimics the early beneficial effect of Roux-en-Y gastric bypass on insulin sensitivity and b-cell Function in type 2 diabetic patients. Diabetes 2013;62:3027-3032
8. Rothberg AE, McEwen LN, Kraftson AT, Fowler CE, Herman WH. Very-low-energy diet for type 2 diabetes: an underutilized therapy? J Diabetes Complications 2014;28:506-510
9. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749-757
10. Steven S, Hollingsworth KG, Al-Mrabeh A, et al. Very low-calorie diet and 6 months of weight stability in type 2 diabetes: pathophysiological changes in responders and nonresponders. Diabetes Care 2016;39:808-815
11. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-163
12. Araneta MRG, Kanaya A, Fujimoto W, et al. Optimum BMI cut-points to screen Asian Americans for type 2 diabetes: The UCSD Filipino Health Study and the North Kohala Study [Abstract]. Diabetes 2014;63(Suppl. 1):A20
13. Wing RR, Bolin P, Brancati FL, et al. ; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med 2013;369:145-154
14. Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity (Silver Spring) 2014;22:5-13
15. Wilding JPH. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014;68:682-691
16. Sacks FM, Bray GA, Carey VJ, et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 2009;360:859-873
17. de Souza RJ, Bray GA, Carey VJ, et al. Effects of 4 weight-loss diets differing in fat, protein, and carbohydrate on fat mass, lean mass, visceral adipose tissue, and hepatic fat: results from the POUNDS LOST trial. Am J Clin Nutr 2012;95:614-625
18. Johnston BC, Kanters S, Bandayrel K, et al. Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA 2014;312:923-933
19. Jensen MD, Ryan DH, Apovian CM, et al. ; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. JAm Coll Cardiol 2014;63(25 Pt B):2985-3023
20. Raynor HA, Anderson AM, Miller GD, et al. ; Look AHEAD Research Group. Partial meal replacement plan and quality of the diet at 1 year: Action for Health in Diabetes (Look AHEAD) Trial. J Acad Nutr Diet 2015;115:731-742
21. U.S. Preventative Services Task Force. Final recommendation statement: abnormal blood glucose and type 2 diabetes mellitus: screening [Internet]. Available from http://www .uspreventiveservicestaskforce.org/page/document/recommendationstatementfinal/screening-for-abnormal-blood-glucose-andtype-2-diabetes. Accessed 18 November 2016
22. Gudzune KA, Doshi RS, Mehta AK, et al. Efficacy of commercial weight-loss programs: an updated systematic review. Ann Intern Med 2015;162:501-512
23. Tsai AG, Wadden TA. The evolution of verylow-calorie diets: an update and meta-analysis. Obesity (Silver Spring) 2006;14:1283-1293
24. Johansson K, Neovius M, Hemmingsson E. Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am J Clin Nutr 2014;99:14-23
25. Yanovski SZ, Yanovski JA. Long-term drug treatment for obesity: a systematic and clinical review. JAMA 2014;311:74-86
26. Greenway FL, Fujioka K, Plodkowski RA, et al. ; COR-I Study Group. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605
27. Pi-Sunyer X, Astrup A, Fujioka K, et al. ; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373:11-22
28. Rubino F, Marescaux J. Effect of duodenaljejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease. Ann Surg 2004;239:1-11
29. Rubino F, Nathan DM, Eckel RH, et al. ; Delegates of the 2nd Diabetes Surgery Summit. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care 2016;39:861-877
30. Sjöström L, Lindroos A-K, Peltonen M, et al. ; Swedish Obese Subjects Study Scientific Group. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004;351:2683-2693
31. Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetesandwithmicrovascular and macrovascular complications. JAMA 2014;311: 2297-2304
32. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA 2012;308:1122-1131
33. Sjöström L, Narbro K, Sjöström CD, et al. ; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-752
34. Sjöström L, Gummesson A, Sjöström CD, et al. ; Swedish Obese Subjects Study. Effects of bariatric surgery on cancer incidence in obese patients in Sweden (Swedish Obese Subjects Study): a prospective, controlled intervention trial. Lancet Oncol 2009;10:653-662
35. Sjöström L, Peltonen M, Jacobson P, et al. Bariatric surgery and long-term cardiovascular events. JAMA 2012;307:56-65
36. Adams TD, Gress RE, Smith SC, et al. Longterm mortality after gastric bypass surgery. N Engl J Med 2007;357:753-761
37. Arterburn DE, Olsen MK, Smith VA, et al. Association between bariatric surgery and long-term survival. JAMA 2015;313:62-70
38. Rubino F, Kaplan LM, Schauer PR, Cummings DE; Diabetes Surgery Summit Delegates. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010;251:399-405
39. Cummings DE, Cohen RV. Beyond BMI: the need for new guidelines governing the use of bariatric and metabolic surgery. Lancet Diabetes Endocrinol 2014;2:175-181
40. Zimmet P, Alberti KGMM, Rubino F, Dixon JB. IDF's view of bariatric surgery in type 2 diabetes. Lancet 2011;378:108-110
41. Kasama K, Mui W, Lee WJ, et al. IFSO-APC consensus statements 2011. Obes Surg 2012; 22:677-684
42. Sjöholm K, Pajunen P, Jacobson P, et al. Incidence and remission of type 2 diabetes in relation to degree of obesity at baseline and 2 year weight change: the Swedish Obese Subjects (SOS) study. Diabetologia 2015;58:1448-1453
43. Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg 2013;23:93-102
44. Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964-973
45. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012;35:1420-1428
46. Brethauer SA,AminianA, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg 2013;258:628-636; discussion 636-637
47. Hsu C-C, Almulaifi A, Chen J-C, et al. Effect of bariatric surgery vs medical treatment on type 2 diabetes in patients with body mass index lower than 35: five-year outcomes. JAMA Surg 2015; 150:1117-1124
48. Schauer PR, Bhatt DL, Kirwan JP, et al. ; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes-3-year outcomes. N Engl J Med 2014;370:2002-2013
49. Yu H, Di J, Bao Y, et al. Visceral fat area as a new predictor of short-term diabetes remission after Roux-en-Y gastric bypass surgery in Chinese patients with a body mass index less than 35 kg/m2. Surg Obes Relat Dis 2015;11:6-11
50. Halperin F, Ding S-A, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg 2014;149:716-726
51. Flum DR, Belle SH, King WC, et al. ; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Perioperative safety in the Longitudinal Assessment of Bariatric Surgery. N Engl J Med 2009;361:445-454
52. Courcoulas AP, Christian NJ, Belle SH, et al. ; Longitudinal Assessment of Bariatric Surgery (LABS) Consortium. Weight change and health outcomes at 3 years after bariatric surgery among individuals with severe obesity. JAMA 2013;310:2416-2425
53. Arterburn DE, Courcoulas AP. Bariatric surgery for obesity and metabolic conditions in adults. BMJ 2014;349:g3961
54. Young MT, Gebhart A, Phelan MJ, Nguyen NT. Use and outcomes of laparoscopic sleeve gastrectomy vs laparoscopic gastric bypass: analysis of the American College of Surgeons NSQIP. J Am Coll Surg 2015;220:880-885
55. Aminian A, Brethauer SA, Kirwan JP, Kashyap SR, Burguera B, Schauer PR. How safe is metabolic/diabetes surgery? Diabetes Obes Metab 2015;17:198-201
56. Birkmeyer NJO, Dimick JB, Share D, et al. ; Michigan Bariatric Surgery Collaborative. Hospital complication rates with bariatric surgery in Michigan. JAMA 2010;304:435-442
57. Altieri MS, Yang J, TelemDA, et al. Lap band outcomes from 19,221 patients across centers and over a decade within the state of New York. Surg Endosc 2016;30:1725-1732
58. Hutter MM, Schirmer BD, Jones DB, et al. First report from the American College of Surgeons Bariatric Surgery Center Network: laparoscopic sleeve gastrectomy has morbidity and effectiveness positioned between the band and the bypass. Ann Surg 2011;254:410-420; discussion 420-422
59. Nguyen NT, Slone JA, Nguyen X-MT, Hartman JS, Hoyt DB. A prospective randomized trial of laparoscopic gastric bypass versus laparoscopic adjustable gastric banding for the treatment of morbid obesity: outcomes, quality of life, and costs. Ann Surg 2009;250: 631-641
60. Birkmeyer JD, Finks JF, O'Reilly A, et al. ; Michigan Bariatric Surgery Collaborative. Surgical skill and complication rates after bariatric surgery. N Engl J Med 2013;369:1434-1442
61. Kirwan JP, Aminian A, Kashyap SR, Burguera B, Brethauer SA, Schauer PR. Bariatric surgery in obese patients with type 1 diabetes. Diabetes Care 2016;39:941-948
62. Rubin JK, Hinrichs-Krapels S, Hesketh R, Martin A, Herman WH, Rubino F. Identifying barriers to appropriate use of metabolic/bariatric surgery for type 2 diabetes treatment: Policy Lab results. Diabetes Care 2016; 39:954-963
63. Fouse T, Schauer P. The socioeconomic impact of morbid obesity and factors affecting access to obesity surgery. Surg Clin North Am 2016;96:669-679
64. Service GJ, Thompson GB, Service FJ, Andrews JC, Collazo-Clavell ML, Lloyd RV. Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery. N Engl J Med 2005;353:249-254
65. Mechanick JI, Kushner RF, Sugerman HJ, et al. ; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery medical guidelines for clinical practice for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient. Obesity (Silver Spring) 2009;17 (Suppl. 1):S1-S70
66. Mechanick JI, Youdim A, Jones DB, et al. ; American Association of Clinical Endocrinologists; Obesity Society; American Society for Metabolic & Bariatric Surgery. Clinical practice guidelines for the perioperative nutritional, metabolic, and nonsurgical support of the bariatric surgery patient-2013 update: cosponsored by American Association of Clinical Endocrinologists, The Obesity Society, and American Society for Metabolic & Bariatric Surgery. Obesity (Silver Spring) 2013;21(Suppl. 1): S1-S27
67. Lee CJ, Clark JM, Schweitzer M, et al. Prevalence of and risk factors for hypoglycemic symptoms after gastric bypass and sleeve gastrectomy. Obesity (Silver Spring) 2015;23:1079-1084
68. Conason A, Teixeira J, Hsu C-H, Puma L, Knafo D, Geliebter A. Substance use following bariatric weight loss surgery. JAMA Surg 2013; 148:145-150
69. Young-Hyman D, Peyrot M. Psychosocial Care for People with Diabetes. 1st ed. Alexandria, VA, American Diabetes Association, 2012
70. Greenberg I, Sogg S, M Perna F. Behavioral and psychological care in weight loss surgery: best practice update. Obesity (Silver Spring) 2009;17:880-884